深圳翰宇药业股份有限公司 关于选举职工董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳翰宇药业股份有限公司（以下简称"公司"或"本公司"）根据《中华人民 共和国公司法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》等法律、法规、规范性文 件及《公司章程》的有关规定，于 2025 年 12 月 4 日召开 2015 年第一次职工大 会，经全体与会职工一致同意，选举唐仁锦先生为公司第六届董事会职工董事（简 历详见附件）。上述职工董事符合《中华人民共和国公司法》《公司章程》等有关 董事任职的资格和条件。 证券代码：300199 证券简称：翰宇药业 公告编号：2025-067 深圳翰宇药业股份有限公司 2025 年 12 月 6 日 附件： 唐仁锦简历 唐仁锦先生， 1990 年 8 月出生，中国国籍，2019 年毕业于巴黎萨克雷大学 治疗化学专业，获工学博士学位。深圳市孔雀计划 C 类人才。自 2019 年起加入 翰宇药业，曾任研发一部资深研究员，现任公司研发一部经理。 本次职工代表大 ...

证券代码：300199 证券简称：翰宇药业 公告编号：2025-066 深圳翰宇药业股份有限公司 2025年第四次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东会存在被否决议案的情况，未通过议案为：《关于董事薪 酬的议案》。 2、本次股东会不涉及变更前次股东会决议。 一、会议召开和出席情况 1、2025年11月17日，深圳翰宇药业股份有限公司（以下简称"公司"或"翰 宇药业"）第六届董事会第十次会议审议通过《关于提请召开2025年第四次临 时股东大会的议案》，详见公司2025年11月18日在中国证监会指定信息披露 网站（http://www.cninfo.com.cn）披露的相关公告。 2025年第四次临时股东会召开的基本情况如下： 会议召集人：公司董事会 会议方式：本次会议采取现场投票和网络投票相结合的方式 会议召开时间：2025年12月5日（周五）下午15:30 会议地点：深圳市龙华区观澜高新园区观盛四路7号翰宇创新产业大楼会 议室 会议主持人：董事长曾少贵先生 本次会议的召集、召开符合《公司法》《上市公司股东 ...

法律意见书 国浩律师（深圳）事务所 关于 深圳翰宇药业股份有限公司 二〇二五年第四次临时股东大会 的 法律意见书 北京·上海·深圳·杭州·广州·昆明·天津·成都·宁波·福州·西安·南京·南宁·济南·重庆 Beijing·Shanghai·Shenzhen·Hangzhou·Guangzhou·Kunming·Tianjin·Chengdu ·Ningbo ·Fuzhou·Xi`an·Nanjing·Nanning·Jinan·Chongqing 苏州·长沙 ·太原·武汉·贵阳·乌鲁木齐·郑州·石家庄·合肥·海南·青岛·南昌·大连·银川·拉孜 Suzhou·Changsha·Taiyuan·Wuhan ·Guiyang·Wulumuqi·Zhengzhou·Shijiazhuang·Hefei·Hainan·Qingdao·Nanchang·Dalian·Yinchuan·Lhatse 香港·巴黎·马德里·硅谷·斯德哥尔摩·纽约·马来西亚·柬埔寨·乌兹别克斯坦·哈萨克斯坦 Hongkong·Paris·Madrid·Silicon Valley·Stockholm·New York·Malaysia·Cambo ...

朱国新是恒瑞医药今年引入的第二位跨国药企核心高管，或将 成为这家公司的7号人物。 作者： 刘晓诺 封图：图虫创意 想出海的"医药一哥"，正不断引进有海外经验的"船长"和"大副"。 2025年12月3日，恒瑞医药（600276.SH/01276.HK）宣布提名聘任朱国新为高级副总裁。公开信 息显示，加入恒瑞之前，朱国新曾是跨国公司礼来的新药研发中心副总裁。 胡新辉任副总裁与首席技术官。据公开资料，2005—2018年，胡新辉曾在葛兰素史克、默沙东、 强生、罗氏上海研发中心等多家跨国药企任职。此后，他先后担任云顶新耀（01952.HK）首席技 术官、凯莱英（002821.SZ/06821.HK）首席技术官兼首席商务官。 孙志刚任副总裁与首席质量官。加入恒瑞医药之前，他是绿叶制药（02186.HK）集团高级副总 裁。他曾在美国FDA工作近12年，负责药品质量审评和GMP现场检查等工作。 尹航任副总裁与肿瘤事业部总经理。他曾任职于诺和诺德，2019年加入礼来中国，2021年8月起任 礼来肿瘤事业部副总裁，直至2025年9月离任。 此外，10月10日，恒瑞医药控股的互联网医疗公司医朵云也迎来新高管：前阿斯利康中国副总裁 ...

Core Viewpoint - A number of A-share pharmaceutical companies are planning to raise funds through refinancing, with a focus on innovative drug projects, reflecting the industry's shift towards innovation due to high R&D costs and long profit cycles [1][3][6]. Group 1: Fundraising Plans - International Medicine announced plans to raise up to 1.008 billion yuan through a private placement, targeting smart healthcare projects and a proton therapy center [3][4]. - Zoli Pharmaceutical plans to issue convertible bonds to raise up to 1.556 billion yuan for an intelligent traditional Chinese medicine factory and product development [3][4]. - A total of 10 pharmaceutical companies have disclosed refinancing plans since the second half of the year, including Shutaishen and Hanyu Pharmaceutical [1][3]. Group 2: Focus on Innovative Drugs - Many of the fundraising projects from these companies are directed towards innovative drug development, with Shutaishen planning to allocate 883 million yuan for R&D of new drugs [5][6]. - Other companies like Anglikang and Apac Pharmaceutical are also focusing their fundraising efforts exclusively on innovative drug projects [5][6]. Group 3: Financial Pressure and Fund Utilization - Some companies are experiencing a decline in cash reserves, with examples like Weiguang Biological, whose cash balance dropped from 256 million yuan to 80 million yuan [7][9]. - The fundraising efforts are aimed at alleviating financial pressure and improving liquidity, with companies like Hanyu Pharmaceutical planning to use part of the funds to reduce their debt ratio [9][10]. - The overall trend indicates that refinancing is a necessary strategy for pharmaceutical companies to ensure project advancement and optimize capital structure [9][10].

Core Viewpoint - The company has indicated that its total production capacity for peptide raw materials exceeds 5 tons, with specific annual production plans being dynamically formulated based on market and collaboration demands [1] Group 1 - The company, Hanyu Pharmaceutical, has confirmed its current production capacity for peptide raw materials is over 5 tons [1] - The annual production schedule for specific products will be determined by market conditions and collaboration needs [1]

Personnel Changes - Yunnan Baiyao announced the election of Zhang Wenxue as chairman and Dong Ming as vice chairman during the first meeting of the 11th board of directors on November 10, 2025 [2] - China National Pharmaceutical Group (Sinopharm) reported the resignation of Zhao Bingxiang from multiple positions, including non-executive director and chairman, with Jin Bin proposed as the new chairman [3] - Huatai Medical announced a board restructuring, nominating several candidates for its third board of directors, including current executives from Mindray Medical [4] - Hanyu Pharmaceutical reported the retirement of its executive director Pinxiang Yu and appointed two new executive directors, Shen Yaping and Tang Yangming [5] - GSK China appointed Sheng Feng as vice president, responsible for market access and commercial operations, effective December 1, 2025 [12] Executive Appointments - Medtronic appointed Larry Xu as vice president for orthopedic and neurosurgery business in China, effective November 10, 2025 [9] - Pfizer China announced the appointment of Su Tianyu as head of the broad market division, effective immediately [10][11] - Eli Lilly appointed Carole Ho as president of the neuroscience division, while Adrienne Brown was promoted to president of the immunology division [15] - Restore Medical appointed Chris Cleary, former senior vice president at Medtronic, as chairman of the board [18] Resignations - Johnson & Johnson announced the departure of Alex He, vice president and head of the PINS division, effective December 31, 2025 [8] - Several executives across various companies, including Chen Changbing from Sinopharm United and Wang Junbo from Guangyu Yuan, submitted their resignations due to work adjustments [3][5]

Market Overview - The chemical pharmaceutical sector increased by 0.16% on December 1, with Changshan Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3914.01, up 0.65%, while the Shenzhen Component Index closed at 13146.72, up 1.25% [1] Top Gainers in Chemical Pharmaceutical Sector - Changshan Pharmaceutical (300255) closed at 67.70, up 8.93% with a trading volume of 353,700 shares and a transaction value of 2.379 billion [1] - Laimei Pharmaceutical (300006) closed at 5.42, up 5.24% with a trading volume of 821,100 shares [1] - Oukang Pharmaceutical (920230) closed at 13.22, up 3.44% with a trading volume of 11,400 shares [1] Top Losers in Chemical Pharmaceutical Sector - Yifang Bio (688382) closed at 27.05, down 8.24% with a trading volume of 315,300 shares [2] - Keyuan Pharmaceutical (301281) closed at 27.96, down 4.51% with a trading volume of 44,300 shares [2] - Kangzhiyue Pharmaceutical (300086) closed at 12.17, down 4.32% with a trading volume of 864,700 shares [2] Capital Flow Analysis - The chemical pharmaceutical sector experienced a net outflow of 1.011 billion from institutional investors, while retail investors saw a net inflow of 466 million [2] - The sector's overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are actively buying [2] Individual Stock Capital Flow - Maiwei Bio (688062) had a net inflow of 48.528 million from institutional investors, but a net outflow of 65.659 million from retail investors [3] - Lijun Group (000513) saw a net inflow of 23.529 million from institutional investors, with a net outflow of 25.007 million from retail investors [3] - Huadong Pharmaceutical (000963) had a net inflow of 18.642 million from institutional investors, while retail investors experienced a net inflow of 10.459 million [3]

宏观 要闻 重要经济指标发布 11月30日，国家统计局服务业调查中心和中国物流与采购联合会发布了中国采购经理指数。数据显示， 11月份制造业采购经理指数为49.2%，比上月上升0.2个百分点，景气水平有所改善；非制造业商务活动 指数为49.5%，比上月下降0.6个百分点，显示非制造业经营活动有所放缓；综合PMI产出指数为 49.7%，比上月下降0.3个百分点，我国经济景气水平总体平稳。 分析认为，12月制造业市场需求仍有趋稳回升空间，并带动企业生产活动稳中有增，年末节庆和冬季消 费相关需求集中释放会带动消费相关服务业有所回升，投资有望继续发挥托底经济的作用。不过，专家 也提出，要围绕"十五五"良好开局进一步加强宏观经济政策逆周期调节力度，显著加大政府公共产品、 公共服务投资规模，进一步有效有力带动企业订单增加。 多部门联合召开科技金融统筹推进机制第一次会议 11月27日，中国人民银行、科技部等部门联合召开科技金融统筹推进机制第一次会议。中国人民银行行 长潘功胜、科技部部长阴和俊出席会议并讲话。 会议强调，明年是"十五五"开局之年，各有关部门要扎实推进各项工作任务落实，常态化运行科技金融 统筹推进机制，强化科金 ...

Group 1 - The core viewpoint of the news is that Hanyu Pharmaceutical has shown significant stock price fluctuations and strong financial performance in recent months, with a notable increase in revenue and net profit year-on-year [1][2][3] Group 2 - As of November 24, Hanyu Pharmaceutical's stock price increased by 2.09% to 18.11 CNY per share, with a total market capitalization of 15.996 billion CNY [1] - The company has experienced a 40.50% increase in stock price year-to-date, but has seen a decline of 6.65% in the last five trading days and 16.89% over the last 20 days [1] - For the period from January to September 2025, Hanyu Pharmaceutical achieved a revenue of 683 million CNY, representing a year-on-year growth of 82.06%, and a net profit of 71.35 million CNY, which is a 305.00% increase compared to the previous year [2] Group 3 - Hanyu Pharmaceutical has not distributed any dividends in the last three years, with a total payout of 417 million CNY since its A-share listing [3] - As of September 30, 2025, the number of shareholders increased to 110,100, with an average of 6,771 circulating shares per person, a decrease of 42.81% from the previous period [2][3] - The largest circulating shareholder is Hong Kong Central Clearing Limited, holding 33.5479 million shares, an increase of 25.8662 million shares from the previous period [3]